Get the Stockscreener App
0.6082
2.58%
-0.0161
After Hours:
.61
0.0018
+0.30%
Vistagen Therapeutics Inc stock is traded at $0.6082, with a volume of 928.37K.
It is down -2.58% in the last 24 hours and down -16.50% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$0.6243
Open:
$0.628
24h Volume:
928.37K
Relative Volume:
0.37
Market Cap:
$24.02M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-0.4531
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-5.73%
1M Performance:
-16.50%
6M Performance:
-80.25%
1Y Performance:
-78.88%
1-Day Range:
$0.6001
$0.63
1-Week Range:
$0.6001
$0.6808
52-Week Range:
$0.6001
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6082 | 24.66M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Downgrade | Maxim Group | Buy → Hold |
| Dec-17-25 | Downgrade | Stifel | Buy → Hold |
| Dec-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit - The AI Journal
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
2026-01-26 | VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit - GlobeNewswire Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen - GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
ROSEN, A LEADING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - marketscreener.com
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - Barchart.com
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
Vistagen Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Vistagen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 16, 2026VTGN - Barchart.com
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - marketscreener.com
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - GuruFocus
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen - GlobeNewswire
Vistagen (VTGN) Stock Plummets 80% After Phase 3 Trial Failure - Intellectia AI
VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
VTGN Investors Encouraged to Seek Lead Plaintiff Role in - GlobeNewswire
Buybacks Report: What is the next catalyst for Vistagen Therapeutics IncTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - ACCESS Newswire
Analyst Upgrade: Is Vistagen Therapeutics Inc attractive for institutional investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - ACCESS Newswire
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Fraud - Intellectia AI
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-01-19 | VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
Vistagen Therapeutics Faces Class Action Lawsuit; Investors Encouraged to Claim Losses - Intellectia AI
VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
Faruqi & Faruqi Investigates Vistagen Investors' Claims Ahead of March 2026 Deadline - Intellectia AI
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistage - GuruFocus
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit - PR Newswire
2026-01-18 | VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
Short Interest in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Rises By 88.9% - Defense World
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Cla - GuruFocus
Vistagen Therapeutics (VTGN) Faces Class Action Over Misleading Trial Results, Stock Plummets 80% - Intellectia AI
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. - PR Newswire
Vistagen Therapeutics Faces Class Action Lawsuit, Shareholders May Claim Compensation - Intellectia AI
Vistagen Therapeutics Faces Class Action Lawsuit for Misleading Investors on Drug Development - Intellectia AI
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):